<DOC>
	<DOCNO>NCT00006487</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy plus radiation therapy treat patient limited-stage small cell lung cancer .</brief_summary>
	<brief_title>S0004 : Combination Chemotherapy Plus Radiation Therapy Treating Patients With Limited-stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility tirapazamine , cisplatin , etoposide concurrently radiotherapy patient limited stage small cell lung cancer . - Determine toxicity treatment regimen patient . - Determine response rate patient treat regimen . OUTLINE : Patients assign one two induction therapy arm . - Arm I : Patients receive induction chemotherapy consist low-dose tirapazamine IV 1 hour cisplatin IV 1 hour day 1 , 8 , 29 , 36 etoposide IV 1 hour day 1-5 29-33 . Patients also undergo radiotherapy concurrently chemotherapy 5 consecutive day week 7 week begin day 1 . - Arm II : Patients receive induction chemotherapy consist high-dose tirapazamine , cisplatin , etoposide , radiotherapy arm I . Patients stable respond disease receive consolidation therapy consist tirapazamine IV 1 hour cisplatin IV 1 hour day 1 week 11 14 etoposide IV 1 hour day 1-3 week 11 14 . Patients follow every 2 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 50 patient ( 25 per arm ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Tirapazamine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm limited stage small cell lung cancer ( SCLC ) No malignant pericardial pleural effusion , include follow : Cytologically positive effusion Exudative effusion attributable etiology No brain metastasis Disease ( measurable nonmeasurable ) must present outside area prior surgical resection PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 2 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine great ULN OR Creatinine clearance least 60 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception No symptomatic sensory neuropathy grade 1 great No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , stage I II cancer complete remission No medical illness would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy SCLC Chemotherapy : No prior systemic chemotherapy SCLC Endocrine therapy : Not specify Radiotherapy : No prior thoracic radiotherapy SCLC Surgery : See Disease Characteristics At least 2 week since prior thoracic major surgery recover</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>